Blogs

Learn how to read a company's Sales-to-Gross-Block ratio in 60 seconds — the asset-productivity test that separates capital-light compounders from capital-heavy laggards. Titan Biotech FY25's ~3.76x reading is the positive illustration.

Tversky & Kahneman's 1981 Asian Disease Problem proved that human preferences reverse under arithmetically identical framings. Indian retail data confirms the effect at industrial scale. Titan Biotech (BSE: 524717) FY25 disclosures publish nearly every material fact in two frames simultaneously — a corporate analogue of the dual-frame discipline the great investors have used for ninety years.

Export Revenue Mix isn't just a percentage — it's a forensic test for customer concentration, currency hedging, and pricing power against global benchmarks. Using Titan Biotech FY25's audited ~34.5% export share across 60+ countries as an educational illustration of disciplined geographic diversification.

A forensic balance-sheet ratio every Indian long-term investor should master, illustrated with Titan Biotech FY25 audited markers (₹11 Cr CWIP, ₹57 Cr Gross Block, ₹3 Cr borrowings, 103% CFO/Operating Profit).